India’s Reliance Freezes Plans For Pharmaceutical Plant, But Ramps Up Entry Into Biopharma With 14 Biosimilars In The Works
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The tough economic environment seems to have short-circuited the ambitions of Reliance Industries - India's largest private sector group - to emerge as a formidable player in the global pharmaceutical industry. Reliance has frozen all its plans to build a finished formulation facility at Jamnagar - a town near the company's super-size petrochemicals refinery complex